Microcap Ledger Immunic, Inc. $IMUX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- New York, United States
- Fiscal year end
- December 31
- Shares outstanding
- 13,644,467 [10-Q 2026-08-11]
What the company doesAI summary of filing
Immunic is a late-stage biotechnology company developing oral small-molecule therapies for neurologic and gastrointestinal diseases. The company's lead program, vidofludimus calcium (IMU-838), is in Phase 3 clinical development for relapsing multiple sclerosis, with top-line data expected by the end of 2026; IMU-856 is in clinical development for gastrointestinal diseases such as celiac disease and inflammatory bowel disease; and IMU-381 is in preclinical testing for neurologic and autoimmune diseases. The company is pre-revenue, having never generated product sales revenue, with accumulated losses of $608.6 million as of December 31, 2025, and funds its operations through equity and warrant offerings. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$66.69M | −$48.30M | $155.10M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$97.17M | −$85.81M | $15.48M | [10-K 2026-02-26] |
| FY ended Dec 2024 | — | −$100.51M | −$84.77M | $35.67M | [10-K 2026-02-26] |
- Quarterly cash burn
- −$24.15M
- Cash runway Estimate
- ~19.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-02-15 | 90,150,869 | [10-K 2025-03-31] |
| 2025-05-14 | 95,817,536 | [10-Q 2025-05-15] |
| 2025-07-31 | 98,650,590 | [10-Q 2025-08-07] |
| 2025-11-07 | 120,284,724 | [10-Q 2025-11-13] |
| 2026-02-20 | 130,464,825 | [10-K 2026-02-26] |
| 2026-04-16 | 136,214,825 | [10-K/A 2026-04-22] |
| 2026-04-30 | 13,621,526 | [10-Q 2026-05-13] |
| 2026-07-31 | 13,644,467 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2026-04-02; declared effective 2026-05-04 [S-3 2026-04-02]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-01-06. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-01-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-06] |
| 2025-06-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-27] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-11 | 8-K | Director or officer change |
| 2026-09-09 | 8-K | Regulation FD disclosure |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 8-K | Results of operations; Director or officer change; Regulation FD disclosure |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-06 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-16 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-14 | 8-K | Regulation FD disclosure |
Alerts for $IMUX
Email me when Immunic, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.